Asset profile

TTI-101 · Tvardi Therapeutics, Inc. (TVRD)

Indication
hepatocellular carcinoma
CompanyTVRDTvardi Therapeutics, Inc.

Tvardi Therapeutics Inca clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting Signal Transducer and Activator of Transcription 3 (STAT3) to treat inflammatory and proliferative diseases with unm…

On the calendar

Timeline

Newest first.

Nov 13, 2026
12:05 PM
TVRDTvardi Therapeutics, Inc.

Tvardi Announces TTI-101 Phase 1b/2 HCC Topline Data Expected Early Q1 2027

OtherSEC 8-K

Registered trials

Registry IDPhaseStatusPrimary completionEnrollmentSites
NCT05671835Phase 2CompletedAug 14, 202510028 of 28 sites in the United States
NCT05668949Phase 1/2WithdrawnSep 23, 20250
NCT05440708Phase 1/2RecruitingMay 25, 202719321 of 21 sites in the United States

More from Tvardi Therapeutics, Inc.

Other drugs and candidates from the same company tracked in this sector.